Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | por |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/53103 |
Resumo: | Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil. |
| id |
CRUZ_d497a354ed3c45e10b2ed65636b71f7c |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/53103 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Kerr, Marlon Wendell AthaydesGama, Fábio MagalhãesIbiapina, Hiochelson Najibe SantosHanna, Fabíola Silva AlvesXabregas, Lilyane AmorimAlves, Eliana BrasilPimentel, João Paulo DinizCarvalho, Maria Perpétuo Socorro SampaioTarragô, Andréa MonteiroCarvalho, Andréa TeixeiraMartins Filho, Olindo AssisCosta, Allyson Guimarães daMalheiro, Adriana2022-06-07T16:28:06Z2022-06-07T16:28:06Z2021KERR, Marlon Wendell Athaydes et al. Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leucemia Patients Undergoing Induction Therapy. Front Oncol., v. 11, 11:696032, 2021. doi: 10.3389/fonc.2021.696032.2234-943Xhttps://www.arca.fiocruz.br/handle/icict/5310310.3389/fonc.2021.696032.porFrontiers Research FoundationBone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil.Universidade Federal do Amazonas. Programa de Pós-Graduação em Imunologia Básica e Aplicada Manaus, AM, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Programa de Pós-Graduação em Ciências da Saúde. Belo Horizonte, MG, Brazil/Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores de Diagnóstico e Monitoração. Belo Horizonte, MG, Brazil.Universidade Federal do Amazonas. Programa de Pós-Graduação em Medicina Tropical. Manaus, AM, Brazil/Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Instituto de Pesquisa Clínica Carlos Borborema. Manaus, AM, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil/Universidade Federal do Amazonas. Programa de Pós-Graduação em Imunologia Básica e Aplicada Manaus, AM, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, BrazilFundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, BrazilFundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, BrazilUniversidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, BrazilUniversidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil/Universidade Federal do Amazonas. Programa de Pós-Graduação em Imunologia Básica e Aplicada Manaus, AM, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/ Fundação Oswaldo Cruz. Instituto René Rachou. Programa de Pós-Graduação em Ciências da Saúde. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores de Diagnóstico e Monitoração. Belo Horizonte, MG, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/ Fundação Oswaldo Cruz. Instituto René Rachou. Programa de Pós-Graduação em Ciências da Saúde. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores de Diagnóstico e Monitoração. Belo Horizonte, MG, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil/Universidade Federal do Amazonas. Programa de Pós-Graduação em Imunologia Básica e Aplicada Manaus, AM, Brazil/Universidade Federal do Amazonas. Programa de Pós-Graduação em Medicina Tropical. Manaus, AM, Brazil/Fundação de Medicina Tropical Dr. Heitor Vieira Dourado. Instituto de Pesquisa Clínica Carlos Borborema. Manaus, AM, Brazil/Universidade Federal do Amazonas. Escola de Enfermagem de Manaus. Manaus, AM, Brazil.Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil/Universidade Federal do Amazonas. Programa de Pós-Graduação em Imunologia Básica e Aplicada Manaus, AM, Brazil.Different factors are used as predictors of unfavorable clinical outcomes in B-Cell Acute Lymphoblastic Leukemia (B-ALL) patients. However, new prognostic markers are needed in order to allow treatment to be more accurate, providing better results and an improved quality of life. In the present study, we have characterized the profile of bone marrow soluble mediators as possible biomarkers for risk group stratification and minimal residual disease (MRD) detection during induction therapy. The study featured 47 newly-diagnosed B-cell acute lymphoblastic leukemia (B-ALL) patients that were categorized into subgroups during induction therapy according to risk stratification at day 15 [Low Risk (LR), Low Risk increasing to High Risk (LR→HR) and High Risk (HR)] and the MRD detection on day 35 (MRD(-) and MRD(+)). Soluble immunological mediators (CXCL8, CCL2, CXCL9, CCL5, CXCL10, IL-1β, IL-6, TNF, IFN-γ, IL-17A, IL-4, IL-5, IL-10 and IL-2) were quantified by cytometric bead array and ELISA. Our findings demonstrated that increased levels of CCL5, IFN-γ and IL-2 at baseline appeared as putative candidates of good prognosis in LR and MRD(-) subgroups, while CCL2 was identified as a consistent late biomarker associated with poor prognosis, which was observed on D35 in HR and MRD(+) subgroups. Furthermore, apparently controversial data regarding IL-17A and TNF did not allow the definition of these molecules as either positive or negative biomarkers. These results contribute to the search for novel prognostic indicators, and indicate the potential of bone marrow soluble mediators in prognosis and follow-up of B-ALL patients during induction therapy.biomarkersbone marrow microenvironmentchemokinescytokinesleukemiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83082https://www.arca.fiocruz.br/bitstream/icict/53103/1/license.txt9193a7c197bc67acd023525e72a03240MD51ORIGINALBone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers.pdfBone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers.pdfapplication/pdf5636223https://www.arca.fiocruz.br/bitstream/icict/53103/2/Bone%20Marrow%20Soluble%20Immunological%20Mediators%20as%20Clinical%20Prognosis%20Biomarkers.pdf644193c66e523b651c26142b3ae9f974MD52icict/531032022-06-07 13:28:06.466oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-07T16:28:06Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| title |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| spellingShingle |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy Kerr, Marlon Wendell Athaydes biomarkers bone marrow microenvironment chemokines cytokines leukemia |
| title_short |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| title_full |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| title_fullStr |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| title_full_unstemmed |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| title_sort |
Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leukemia Patients Undergoing Induction Therapy |
| author |
Kerr, Marlon Wendell Athaydes |
| author_facet |
Kerr, Marlon Wendell Athaydes Gama, Fábio Magalhães Ibiapina, Hiochelson Najibe Santos Hanna, Fabíola Silva Alves Xabregas, Lilyane Amorim Alves, Eliana Brasil Pimentel, João Paulo Diniz Carvalho, Maria Perpétuo Socorro Sampaio Tarragô, Andréa Monteiro Carvalho, Andréa Teixeira Martins Filho, Olindo Assis Costa, Allyson Guimarães da Malheiro, Adriana |
| author_role |
author |
| author2 |
Gama, Fábio Magalhães Ibiapina, Hiochelson Najibe Santos Hanna, Fabíola Silva Alves Xabregas, Lilyane Amorim Alves, Eliana Brasil Pimentel, João Paulo Diniz Carvalho, Maria Perpétuo Socorro Sampaio Tarragô, Andréa Monteiro Carvalho, Andréa Teixeira Martins Filho, Olindo Assis Costa, Allyson Guimarães da Malheiro, Adriana |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Kerr, Marlon Wendell Athaydes Gama, Fábio Magalhães Ibiapina, Hiochelson Najibe Santos Hanna, Fabíola Silva Alves Xabregas, Lilyane Amorim Alves, Eliana Brasil Pimentel, João Paulo Diniz Carvalho, Maria Perpétuo Socorro Sampaio Tarragô, Andréa Monteiro Carvalho, Andréa Teixeira Martins Filho, Olindo Assis Costa, Allyson Guimarães da Malheiro, Adriana |
| dc.subject.en.pt_BR.fl_str_mv |
biomarkers bone marrow microenvironment chemokines cytokines leukemia |
| topic |
biomarkers bone marrow microenvironment chemokines cytokines leukemia |
| description |
Universidade do Estado do Amazonas. Programa de Pós-Graduação em Ciências Aplicadas à Hematologia. Manaus, AM, Brazil/Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas. Diretoria de Ensino e Pesquisa. Manaus, AM, Brazil. |
| publishDate |
2021 |
| dc.date.issued.fl_str_mv |
2021 |
| dc.date.accessioned.fl_str_mv |
2022-06-07T16:28:06Z |
| dc.date.available.fl_str_mv |
2022-06-07T16:28:06Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
KERR, Marlon Wendell Athaydes et al. Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leucemia Patients Undergoing Induction Therapy. Front Oncol., v. 11, 11:696032, 2021. doi: 10.3389/fonc.2021.696032. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/53103 |
| dc.identifier.issn.pt_BR.fl_str_mv |
2234-943X |
| dc.identifier.doi.none.fl_str_mv |
10.3389/fonc.2021.696032. |
| identifier_str_mv |
KERR, Marlon Wendell Athaydes et al. Bone Marrow Soluble Immunological Mediators as Clinical Prognosis Biomarkers in B-Cell Acute Lymphoblastic Leucemia Patients Undergoing Induction Therapy. Front Oncol., v. 11, 11:696032, 2021. doi: 10.3389/fonc.2021.696032. 2234-943X 10.3389/fonc.2021.696032. |
| url |
https://www.arca.fiocruz.br/handle/icict/53103 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Frontiers Research Foundation |
| publisher.none.fl_str_mv |
Frontiers Research Foundation |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/53103/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/53103/2/Bone%20Marrow%20Soluble%20Immunological%20Mediators%20as%20Clinical%20Prognosis%20Biomarkers.pdf |
| bitstream.checksum.fl_str_mv |
9193a7c197bc67acd023525e72a03240 644193c66e523b651c26142b3ae9f974 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008955323973632 |